These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3877257)

  • 1. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
    Schultz W; Studer A; Jonsson G; Sundström E; Mefford I
    Neurosci Lett; 1985 Aug; 59(2):225-32. PubMed ID: 3877257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys.
    Schultz W; Scarnati E; Sundström E; Tsutsumi T; Jonsson G
    Exp Brain Res; 1986; 63(1):216-20. PubMed ID: 3488228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficits in reaction times and movement times as correlates of hypokinesia in monkeys with MPTP-induced striatal dopamine depletion.
    Schultz W; Studer A; Romo R; Sundström E; Jonsson G; Scarnati E
    J Neurophysiol; 1989 Mar; 61(3):651-68. PubMed ID: 2785168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys.
    Wolters EC; Kebabian JC; Guttman M; Mak E; Pate BD; Calne DB
    Neurosci Lett; 1988 Dec; 95(1-3):257-61. PubMed ID: 3265771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions.
    Schultz W; Scarnati E; Sundström E; Romo R
    Neuroscience; 1989; 31(1):219-30. PubMed ID: 2528081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
    Alexander GM; Schwartzman RJ; Brainard L; Gordon SW; Grothusen JR
    Brain Res; 1992 Aug; 588(2):261-9. PubMed ID: 1356591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
    Crossman AR; Clarke CE; Boyce S; Robertson RG; Sambrook MA
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):428-35. PubMed ID: 3119180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology.
    Imai H; Nakamura T; Endo K; Narabayashi H
    Brain Res; 1988 Dec; 474(2):327-32. PubMed ID: 3264746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
    Di Paolo T; Bédard P; Daigle M; Boucher R
    Brain Res; 1986 Aug; 379(2):286-93. PubMed ID: 2427166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
    Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
    Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA; Rothblat DS; Joyce JN; Schneider JS
    Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficits in operant behaviour in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Schneider JS; Unguez G; Yuwiler A; Berg SC; Markham CH
    Brain; 1988 Dec; 111 ( Pt 6)():1265-85. PubMed ID: 3264739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.
    Porrino LJ; Burns RS; Crane AM; Palombo E; Kopin IJ; Sokoloff L
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5995-9. PubMed ID: 3497401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
    Bédard PJ; Di Paolo T; Falardeau P; Boucher R
    Brain Res; 1986 Aug; 379(2):294-9. PubMed ID: 3488796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
    Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
    Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Clarke CE; Boyce S; Robertson RG; Sambrook MA; Crossman AR
    J Neurol Sci; 1989 May; 90(3):307-14. PubMed ID: 2786926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
    Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
    Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.